|
| Treatment | Description | Groups |
|
| STZ | Diabetic mice were induced with multiple low doses of streptozotocin (MLD-STZ). They received during five days consecutive intraperitoneal injections (i.p) of STZ (Sigma-Aldrich; 45 mg/kg) dissolved in 0.1 M sodium citrate, pH 4.5 [30] | STZ |
|
| STZ/TcS | Mice with MLD-STZ and injections of T. crassiceps soluble antigens | |
| With 50 μg of TcS i.p. 3 times for a week, one week before, and during the week of induction with MLD-STZ | STZ/TcS-1 |
| Treated constantly with 50 μg i.p. 3 times per week, one week before, during treatment with MLD-STZ, and for 6 weeks post induction until euthanasia | STZ/TcS-2 |
| Treated with 50 μg i.p. 3 times per week, starting 1 week post induction of T1D and continuing until sacrifice | STZ/TcS-3 |
| Treated with 100 μg i.p. 3 times per week during 1 week post induction of T1D and for 6 weeks afterward | STZ/TcS-4 |
| Treated with 200 μg i.p. 3 times per week, starting 1 week post induction T1D and continuing for 6 weeks | STZ/TcS-5 |
|
| STZ/TcES | Animals treated with injections of T. crassiceps excreted/secreted antigens with MLD-STZ | |
| Treated with 50 μg i.p. 3 times per week, one week before, during treatment with MLD-STZ, and for 6 weeks post induction | STZ/TcES-1 |
| Treated with 50 μg i.p. 3 times per week started 1 week post induction of T1D for the rest of the treatment period | STZ/TcES-2 |
| Treated with 100 μg i.p. 3 times per week since first week post induction of T1D for the rest of the treatment period | STZ/TcES-3 |
| Treated with 200 μg i.p. 3 times per week, started one week after induction of T1D and during 6 weeks | STZ/TcES-4 |
|
| Liposomes | Six- to eight-week-old mice were infected i.p. with 20 cysticerci, and then we waited 6 weeks post infection to induce diabetes by MLD-STZ. We chose this time period to induce diabetes because we know by a previous report from our group that the change in the immune response to a Th2 response and the appearance of AAMϕs have been established to occur in the sixth to eighth week post infection [31]. Macrophages were depleted in vivo using dichloromethylene diphosphonate (clodronate) encapsulated in liposomes. Treatment of liposome injections was followed as Reyes et al. [31] | |
| In the second week after T1D-induction, mice were treated with i.p. injections of clodronate liposomes (Cl) or PBS liposomes (200 μl/mouse i.p. 3 times/week) for 5 weeks post T1D induction | STZ Cl
STZ PBS |
| Two weeks after T1D induction by MLD-STZ, T. crassiceps-infected and T. crassiceps-uninfected mice were injected i.p. with Cl liposomes and PBS liposomes (200 μl/mouse i.p. 3 times/week) for 5 weeks post T1D induction | STZ/Tc Cl
STZ/Tc PBS |
| An equivalent treatment with clodronate liposomes was done in TcSA-treated Balb/c mice. Animals were injected on a similar schedule to STZ/TcS-2, the second week before T1D induction and continuing for 4 weeks post induction. Blood glucose levels were measured for 4 weeks | STZ/TcS Cl
STZ/TcS PBS |
|
| Untreated | Receiving neither antigens nor MLD-STZ | Untreated |
|
